Roche Holding AG (ROG.VX)
253.10CHF
11:31am EDT
CHF2.40 (+0.96%)
CHF250.70
CHF251.90
CHF254.80
CHF251.40
1,399,571
1,752,700
CHF258.60
CHF148.40
ROG.VX
About
Overall
| Beta: | 0.86 |
| Market Cap (Mil.): | CHF216,292.50 |
| Shares Outstanding (Mil.): | 862.56 |
| Dividend: | 7.35 |
| Yield (%): | 2.84 |
Financials
| ROG.VX | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | 22.48 | 34.14 | 34.28 |
| EPS (TTM): | 11.15 | -- | -- |
| ROI: | 22.90 | 19.49 | 18.85 |
| ROE: | 71.75 | 20.26 | 19.72 |
Immune system cancer drugs tipped to be a $35 billion market
LONDON - A new wave of medicines that tap the power of the immune system to fight cancer could become the biggest drug class in history, with potential sales of $35 billion a year.
Roche presents automated lab solution at conference
ZURICH, May 22 - Roche Holding AG : * Media release: Roche presents new, fully automated lab solution at europe's
Roche, Sigma teamed up for failed Life Technologies bid: sources
NEW YORK - Roche Holding AG teamed up with Sigma-Aldrich Corp to make an unsuccessful bid for Life Technologies Corp earlier this year, people familiar with the matter said.
Roche, Sigma teamed up for failed Life Technologies bid -sources
NEW YORK, May 21 - Roche Holding AG teamed up with Sigma-Aldrich Corp to make an unsuccessful bid for Life Technologies Corp earlier this year, people familiar with the matter said.
Regeneron settles all pending litigation with Roche's Genentech
May 20 - Regeneron Pharmaceuticals Inc said it settled all pending litigation with Roche Holding AG's unit Genentech on the company's eye drug, Eylea, and cancer drug, Zaltrap.
Data show new Roche leukemia drug may improve on Rituxan
- An experimental leukemia treatment that Roche Holding AG hopes will improve upon its best-selling cancer drug Rituxan delayed disease progression twice as long as chemotherapy, according to preliminary trial data released on Wednesday.
CORRECTED-Data show new Roche leukemia drug may improve on Rituxan
(Corrects paragraph 12 to show Biogen has stake in new drug)
Data shows new Roche leukemia drug may improve on Rituxan
- An experimental leukemia treatment that Roche Holding AG hopes will improve upon its best-selling cancer drug Rituxan delayed disease progression twice as long as chemotherapy, according to preliminary trial data released on Wednesday.
Roche immunotherapy shows response over range of cancers
May 15 - An experimental Roche Holding AG drug that helps the immune system attack tumors was well tolerated and demonstrated an impressive effect against a variety of cancers, according to preliminary trial results released on Wednesday.
Data shows new Roche leukemia drug may improve on Rituxan
May 15 - An experimental leukemia treatment that Roche Holding AG hopes will improve upon its best-selling cancer drug Rituxan delayed disease progression twice as long as chemotherapy, according to preliminary trial data released on Wednesday.
Earnings vs. 
Estimates
Analyst Research Reports
| Report Title | Price |
|---|---|
|
Provider: Reuters Investment Profile
|
$20.00
|
|
Provider: Reuters Investment Profile
|
$20.00
|
|
Provider: Wright Reports
|
$506.00
|
|
Provider: Validea
|
$12.00
|
|
Provider: Thomson Reuters StreetEvents
|
$75.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
